These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 24145957)

  • 21. Insights into the molecular pathogenesis of progression in multiple sclerosis: potential implications for future therapies.
    Imitola J; Chitnis T; Khoury SJ
    Arch Neurol; 2006 Jan; 63(1):25-33. PubMed ID: 16401734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The enigma of multiple sclerosis: inflammation and neurodegeneration cause heterogeneous dysfunction and damage.
    Owens T
    Curr Opin Neurol; 2003 Jun; 16(3):259-65. PubMed ID: 12858060
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Axonal damage and its significance for the concept of neurodegeneration in multiple sclerosis].
    Recks MS; Bader J; Kaiser CC; Schroeter M; Fink GR; Addicks K; Kuerten S
    Fortschr Neurol Psychiatr; 2011 Mar; 79(3):161-70. PubMed ID: 21394707
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protecting axons in multiple sclerosis.
    Wilkins A; Scolding N
    Mult Scler; 2008 Sep; 14(8):1013-25. PubMed ID: 18632772
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MS as a gateway disease.
    Lublin FD
    J Neurol Sci; 2013 Oct; 333(1-2):73-5. PubMed ID: 23578792
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic decision making in a new drug era in multiple sclerosis.
    Keegan BM
    Semin Neurol; 2013 Feb; 33(1):5-12. PubMed ID: 23709208
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The only way to manage neurodegeneration in MS is to prevent it with effective anti-inflammatory therapy: yes.
    Evangelou N
    Mult Scler; 2012 Dec; 18(12):1680-1. PubMed ID: 23235776
    [No Abstract]   [Full Text] [Related]  

  • 28. The endocannabinoid system in the inflammatory and neurodegenerative processes of multiple sclerosis and of amyotrophic lateral sclerosis.
    Rossi S; Bernardi G; Centonze D
    Exp Neurol; 2010 Jul; 224(1):92-102. PubMed ID: 20353778
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination therapy in multiple sclerosis.
    Fernández O
    J Neurol Sci; 2007 Aug; 259(1-2):95-103. PubMed ID: 17507031
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neurodegeneration in autoimmune CNS inflammation.
    Herz J; Zipp F; Siffrin V
    Exp Neurol; 2010 Sep; 225(1):9-17. PubMed ID: 19961850
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gray matter atrophy in multiple sclerosis: a longitudinal study.
    Fisher E; Lee JC; Nakamura K; Rudick RA
    Ann Neurol; 2008 Sep; 64(3):255-65. PubMed ID: 18661561
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The therapeutic use of gene therapy in inflammatory demyelinating diseases of the central nervous system.
    Furlan R; Pluchino S; Martino G
    Curr Opin Neurol; 2003 Jun; 16(3):385-92. PubMed ID: 12858077
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Curcumin has bright prospects for the treatment of multiple sclerosis.
    Xie L; Li XK; Takahara S
    Int Immunopharmacol; 2011 Mar; 11(3):323-30. PubMed ID: 20828641
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Neuronal injury in multiple sclerosis].
    Correale J; Meli F; Ysrraelit C
    Medicina (B Aires); 2006; 66(5):472-85. PubMed ID: 17137182
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MS: prevention of neural damage by early intervention.
    Kira J
    Lancet Neurol; 2008 Jan; 7(1):3-5. PubMed ID: 18093546
    [No Abstract]   [Full Text] [Related]  

  • 37. Naturally Occurring Monoclonal Antibodies and Their Therapeutic Potential for Neurologic Diseases.
    Wootla B; Watzlawik JO; Warrington AE; Wittenberg NJ; Denic A; Xu X; Jordan LR; Papke LM; Zoecklein LJ; Pierce ML; Oh SH; Kantarci OH; Rodriguez M
    JAMA Neurol; 2015 Nov; 72(11):1346-53. PubMed ID: 26389734
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cortical projection neurons as a therapeutic target in multiple sclerosis.
    Beutel T; Dzimiera J; Kapell H; Engelhardt M; Gass A; Schirmer L
    Expert Opin Ther Targets; 2020 Dec; 24(12):1211-1224. PubMed ID: 33103501
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The only way to manage neurodegeneration in MS is to prevent it with effective anti-inflammatory therapy: no.
    Wilkins A
    Mult Scler; 2012 Dec; 18(12):1682-3. PubMed ID: 23235777
    [No Abstract]   [Full Text] [Related]  

  • 40. The only way to manage neurodegeneration in MS is to prevent it with effective anti-inflammatory therapy: commentary.
    Hutchinson M
    Mult Scler; 2012 Dec; 18(12):1684-5. PubMed ID: 23235778
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.